A$0.045 close: DNA.AX Donaco International ASX 17 Mar 2026 oversold bounce

DNA.AX stock closed at A$0.045 on the ASX on 17 Mar 2026, presenting a short-term oversold bounce opportunity. Trading volume was only 3,412 shares versus a 50-day average of 1,330,450.00, concentrating risk but also creating a low-liquidity bounce setup. We look at valuation, technicals, Meyka AI grading, and price targets to frame a measured short-term trade idea for investors seeking an oversold rebound.

DNA.AX stock: why an oversold bounce looks possible

Donaco International (DNA.AX) operates casinos in Cambodia and Vietnam and shows strong profit margins, with a trailing net margin of 93.76%. The stock is thinly traded today with volume at 3,412.00, creating price moves on small flows. Low liquidity and recent YTD strength of 60.71% suggest sellers may be exhausted and a bounce can follow a short squeeze or positive operational news.

DNA.AX stock valuation and financials

Valuation is cheap by several measures: price to earnings is 1.50, price to book is 0.37, and price to sales is 1.40. EPS is 0.03 and market capitalisation is A$55,535,856.00. Return on equity is 27.18%, and free cash flow yield is 26.47%, indicating cash-generative operations despite a small market cap.

DNA.AX stock technicals and volume

The 50-day average price is A$0.0429 and the 200-day average is A$0.03621, so the current price sits above both averages. Daily range was A$0.044–A$0.045. Low relative volume (0.0026) risks false signals, but a genuine oversold bounce would show a three-day volume pickup above the 50-day average and a close above A$0.055 to confirm short-term momentum.

Meyka AI rates DNA.AX with a score out of 100

Meyka AI rates DNA.AX with a score out of 100: 68.60 (Grade B, HOLD). This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The company rating shows strengths in ROE and ROA but flags a conservative DCF view. This grade is informational and not financial advice.

DNA.AX stock price forecast and targets

Meyka AI’s forecast model projects a 12-month price of A$0.03348, implying -25.60% versus the current A$0.045. For an oversold bounce trade we set a short-term rebound target at A$0.060 (upside 33.33%) and a stretch target at A$0.090 (upside 100.00%). Forecasts are model-based projections and not guarantees.

Risks and catalysts for DNA.AX stock

Key near-term catalysts include regional tourism recovery, promotional casino events, and improved liquidity. Major risks are thin trading, regulatory action in host countries, and a 50-day average volume gap that can magnify downside. Watch for earnings updates and any guidance shifts ahead of the next earnings date on 24 Jul 2025.

Final Thoughts

DNA.AX stock at A$0.045 offers a classic oversold bounce setup driven by thin volume and cheap valuation. Short-term traders can design a limited-risk entry sized for low liquidity and target A$0.060 for an initial exit. Fundamental metrics look attractive — PE 1.50, ROE 27.18%, and free cash flow yield 26.47% — but Meyka AI’s 12-month model projects A$0.03348, implying -25.60% from current levels. That creates a split view: a tactical bounce is plausible, while medium-term downside remains. Use tight stops and monitor daily volume spikes and company news. We use Meyka AI as an AI-powered market analysis platform to quantify both the bounce potential and the model-based downside. Sources: Donaco corporate site and ASX company page for filings and price data source source.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.